Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Open-Label Phase 1 Study to Evaluate the Safety of SGN-35T in Patients with Relapsed/Refractory CD30-Expressing Lymphoid Malignancies (SGN35T-001; trial in progress)

Tatyana Feldman, Hun Ju Lee, Gizelle Popradi, Graham P. Collins, Daniel Morillo, Ming Jin Yan, Tara Chen, Youn H. Kim

Blood (2024) 144 (Supplement 1): 6356.

https://doi.org/10.1182/blood-2024-200265

Published: 2024

Journal Articles

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Jasmine Zain, Swaminathan P Iyer, Enrica Marchi, Mitul Gandhi, Youn H. Kim, Michael S. Khodadoust, Jonathan E. Brammer, Christina Poh, Pierluigi Porcu, Kimberley Dilley, Matthias Will, Andrea Kantor, Cathrine Leonowens, Nenad Tomasevic, H. Miles Prince, Steven Horwitz

Blood (2024) 144 (Supplement 1): 980.

https://doi.org/10.1182/blood-2024-206053

Published: 2024

Journal Articles

Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma

Leyla Bojanini, Melba Herrera, Shufeng Li, Tarek Bandali, Nicole Y. Xu, Abdullah A. Ahmed, Michael S. Khodadoust, Youn H. Kim

Blood (2024) 144 (Supplement 1): 1677.

https://doi.org/10.1182/blood-2024-198783

Published: 2024

Journal Articles

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Blood (2024) 144 (Supplement 1): 3056.

https://doi.org/10.1182/blood-2024-200596

Published: 2024

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Blood (2024) 144 (Supplement 1): 466.

https://doi.org/10.1182/blood-2024-194796

Published: 2024

Journal Articles

Genetic alteration of class I HLA in cutaneous T-cell lymphoma

Alexa C Kwang, George E Duran, Sebastian Fernandez-Pol, Safa Najidh, Shufeng Li, Armando N Bastidas Torres, Erica B Wang, Melba Herrera, Tarek I Bandali, David M Kurtz, Youn H Kim, Michael S Khodadoust

Blood blood.2024024817.

https://doi.org/10.1182/blood.2024024817

Published: 2024

Includes: Supplemental data

Journal Articles

Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: A Post Hoc Analysis Examining Disease Burden and Patient Characteristics from the Phase 3 Mavoric Trial in Mycosis Fungoides and Sézary Syndrome

Michi M Shinohara, Youn H. Kim, Kevin Molloy, Pietro Quaglino, Julia Scarisbrick, Susan R. Thornton, Kerry Sandilands, Jen E Liu, Annabel Nixon, Angela Williams, Pablo L. Ortiz-Romero

Blood (2023) 142 (Supplement 1): 1704.

https://doi.org/10.1182/blood-2023-188808

Published: 2023

Journal Articles

Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability

Blood (2023) 142 (Supplement 1): 1702.

https://doi.org/10.1182/blood-2023-184898

Published: 2023

Journal Articles

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Blood (2023) 142 (Supplement 1): 185.

https://doi.org/10.1182/blood-2023-173806

Published: 2023

Journal Articles

Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1715.

https://doi.org/10.1182/blood-2023-190775

Published: 2023

Journal Articles

Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome

Michael S. Khodadoust, Eric Mou, Youn H. Kim

Blood (2023) 141 (7): 695–703.

https://doi.org/10.1182/blood.2020008241

Published: 2023

Journal Articles

Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Francine M. Foss, Youn H. Kim, H. Miles Miles Prince, Timothy M. Kuzel, Costas K. Yannakou, Chean Eng Ooi, Dongyuan Xing, Nicholas Sauter, Preeti Singh, Myron Czuczman, Madeleine Duvic

Blood (2022) 140 (Supplement 1): 1491–1492.

https://doi.org/10.1182/blood-2022-166916

Published: 2022

Journal Articles

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Martine Bagot, Youn H. Kim, Pablo L. Ortiz-Romero, Pier Luigi Zinzani, Neha Mehta-Shah, Olivier Dereure, Marie Beylot-Barry, Stéphane Dalle, Eric D Jacobsen, Auris Huen, Andrea Combalia, Maxime Battistella, Alejandro A. Gru, Hélène Moins-Teisserenc, Michael S. Khodadoust, Julien Viotti, Christine Paiva, Marianna Muller, Pierluigi Porcu

Blood (2022) 140 (Supplement 1): 3760–3761.

https://doi.org/10.1182/blood-2022-160239

Published: 2022

Journal Articles

Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-Cell Lymphomas

Eric Mou, Sebastian Fernandez-Pol, Shufeng Li, Youn H. Kim, Michael S. Khodadoust

Blood (2022) 140 (Supplement 1): 6552–6553.

https://doi.org/10.1182/blood-2022-158610

Published: 2022

Journal Articles

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Yuqin Song, Ning Ding, Dok Hyun Yoon, John C. Reneau, Ryan A. Wilcox, Won Seog Kim, Youn H. Kim, Michael S. Khodadoust, Tatyana A. Feldman, Costas K. Yannakou, Pratyush Giri, Jonathan E Brammer, Lih-Yun Hsu, Hongwei Yuan, Erik Verner, Suresh Mahabhashyam, Richard A. Miller

Blood (2022) 140 (Supplement 1): 8857–8859.

https://doi.org/10.1182/blood-2022-159177

Published: 2022

Journal Articles

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Blood (2022) 140 (5): 419–437.

https://doi.org/10.1182/blood.2021012057

Published: 2022

Journal Articles

Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma

Sara Beygi, George E. Duran, Sebastian Fernandez-Pol, Alain H. Rook, Youn H. Kim, Michael S. Khodadoust

Blood (2022) 139 (26): 3732–3736.

https://doi.org/10.1182/blood.2021014468

Published: 2022

Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Blood (2021) 138 (Supplement 1): 2448.

https://doi.org/10.1182/blood-2021-154490

Published: 2021

Journal Articles

Resistance to Mogamulizumab Is Associated with Loss of CCR4 in Cutaneous T Cell Lymphoma

Sara Beygi, Sebastian Fernandez-Pol, George Duran, Youn H. Kim, Michael S. Khodadoust

Blood (2021) 138 (Supplement 1): 1325.

https://doi.org/10.1182/blood-2021-153177

Published: 2021

Journal Articles

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Steven M. Horwitz, Tatyana A. Feldman, Jing C. Ye, Michael S. Khodadoust, Javier Munoz, Paul A. Hamlin, Youn H. Kim, Ryan A. Wilcox, Manish R. Patel, Greg P. Coffey, Muhtarjan Osman, Jaymes S Holland, Cristina B Guzman, Sonali M. Smith

Blood (2021) 138 (Supplement 1): 622.

https://doi.org/10.1182/blood-2021-148352

Published: 2021

NARROW

Open-Label Phase 1 Study to Evaluate the Safety of SGN-35T in Patients with Relapsed/Refractory CD30-Expressing Lymphoid Malignancies (SGN35T-001; trial in progress)

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Genetic alteration of class I HLA in cutaneous T-cell lymphoma

Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: A Post Hoc Analysis Examining Disease Burden and Patient Characteristics from the Phase 3 Mavoric Trial in Mycosis Fungoides and Sézary Syndrome

Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma

Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome

Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-Cell Lymphomas

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Resistance to Mogamulizumab Is Associated with Loss of CCR4 in Cutaneous T Cell Lymphoma

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only